Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7405-7414

  Bobola, Michael S ^a,b   Finn, Laura S ^a,c   Ellenbogen, Richard G ^a,b   Geyer, J Russell ^a,b   Berger, Mitchel S ^d   Braga, Justin M ^a   Meade, Elizabeth H ^a,b   Gross, Mary E ^a   Silber, John R ^b  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; LOMUSTINE; REDOX EFFECTOR FACTOR 1; SMALL INTERFERING RNA; TEMOZOLOMIDE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL NUCLEUS; CHILD; CONTROLLED STUDY; DNA REPAIR; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENDER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; PRIORITY JOURNAL; REGRESSION ANALYSIS; TREATMENT OUTCOME; TUMOR GROWTH;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; BRAIN; BRAIN NEOPLASMS; CARMUSTINE; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MALE; MEDULLOBLASTOMA; MULTIVARIATE ANALYSIS; NEUROECTODERMAL TUMORS, PRIMITIVE; OLIGONUCLEOTIDES, ANTISENSE; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION;

EID: 27144474248     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1068     Document Type: Article

References (44)

1. McNeil DE, Cote TR, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol 2002;39:190-4.
2. Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 2004;31:666-75.
3. Koeller KK, Rushing EJ. From the archives of the AFIP: medulloblastoma:a comprehensive review with radiologic-pathologic correlation. Radiographics 2003;23:1613-37.
4. Giordana MT, Schiffer P, Lanotte M, Girardi P, Chio A. Epidemiology of adult medulloblastoma. Int J Cancer 1999;80:689-92.
5. Ellison D. Classifying the medulloblastoma:insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 2002;28:257-82.
6. Packer RJ, Rood BR, Mac Donald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg 2003;39:60-7.
7. Chintagumpala M, Berg S, Blaney SM. Treatment controversies in medulloblastoma. Curr Opin Oncol 2001;13:154-9.
8. Eberhart CG, Burger PC. Anaplasia and grading in medulloblastomas. Brain Pathol 2003;13:376-85.
9. Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ. What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 2003;7:53-66.
10. Cohen BH, Packer RJ. Chemotherapy for medulloblastomas and primitive neuroectodermal tumors. J Neurooncol 1996;29:55-68.
11. Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004;5:399-408.
12. Demple B, Harrison L. Repair of oxidative damage to DNA: enzymology and biology. Annu Rev Biochem 1994;63:915-48.
13. Krokan HE, Nilsen H, Skorpen F, Otterlei M, Slupphaug G. Base excision repair of DNA in mammalian cells. FEBS Lett 2000;476:73-7.
14. Lhomme J, Constant J-F, Demeunyck M. Abasic DNA structure, reactivity and recognition. Biopol (Nucleic Acid Sci) 1999;52:65-83.
15. Loeb LA, Preston BD. Mutagenesis by apurinic/apyrimidinic sites. Annu Rev Genet 1986;20:201-30.
16. Sutton MD, Walker GC. Managing DNA polymerases: coordinating DNA replication, DNA repair, and DNA recombination. Proc Natl Acad Sci USA 2001;98:8342-9.
17. Boiteux S, Guillet M. Abasic sites in DNA: repair and biological consequences in Saccharomyces cerevisiae. DNA Repair 2004;3:1-12.
18. Evans AR, Limp-Foster M, Kelley MR. Going APE over ref-1. Mutat Res 2000;461:83-108.
19. Fritz G, Grosch S, Tomicic M, Kaina B. APE/Ref-1 and the mammalian response to genotoxic stress. Toxicology 2003;193:67-78.
20. Bobola MS, Emond MJ, Blank A, et al. Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy. Clin Cancer Res 2004;10:7875-83.
21. Silber JR, Bobola MS, Blank A, et al. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin Cancer Res 2002;8:3008-18.
22. Bobola MS, Blank A, Berger MS, Stevens BA, Silber JR. Apurinic/apyrimdinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res 2001;7:3510-18.
23. 6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 1998;58:1068-73.
24. Chen D, Herman V, Demple B. Two distinct human diesterases that act on 3′-fragments of deoxyribose in radical damaged DNA. Nucleic Acids Res 1991;19:5907-14.
25. Rossi O, Carrozzino F, Cappelli E, Carli F, Frosina G. Analysis of repair of abasic sites in early onset breast cancer patients. Int J Cancer 2000;85:21-6.
26. Keles GE, Berger MS, Srinivasan J, Kolstoe DD, Bobola MS, Silber JR. Establishment and characterization of four human medulloblastoma-derived cell lines. Oncol Res 1995;7:493-503.
27. Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma:enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 2004;3:679-86.
28. 6-methylguanine-DNA methyltransferase to monofunctional alkylating agent resistance in human brain tumor-derived cell lines. Mol Carcinog 1995;13:70-80.
29. Flaherty DM, Monick MM, Hunninghake GW. AP endonucleases and the many functions of Ref-1. Am J Respir Cell Mol Biol 2001;25:664-7.
30. Ono Y, Furuta T, Ohmoto T, Akiyama K, Seki S. Stable expression in rat glioma cells of sense and antisense nucleic acids to a human multifunctional enzyme, APEX nuclease. Mutat Res 1994;315:55-63.
31. Walker LJ, Craig RB, Harris AL, Hickson ID. A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res 1994;22:4884-9.
32. Chen DS, Olkowski ZL. Biological response of human apurinic endonuclease to radiation-induced DNA damage. Ann NY Acad Sci 1994;29:306-8.
33. Gaiddon C, Moorthy NC, Prives C. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. EMBO J 1999;18:5609-21.
34. Roth TJ, Xu Y, Luo M, Kelley MR. Human-yeast chimeric repair protein protects mammalian cells against alkylating agents: enhancement of MGMT protection. Cancer Gene Ther 2003;10:603-10.
35. Ono Y, Watanabe M, Inoue Y, et al. Developmental expression of APEX nuclease, a multifunctional DNA repair enzyme, in mouse brains. Brain Res Dev Brain Res 1995;86:1-6.
36. Wilson TM, Rivkees SA, Deutsch WA, Kelley MR. Differential expression of the apurinic/apyrimidinic endonuclease (APE/ref-1) multifunctional DNA base excision repair gene during fetal development and in adult rat brain and testis. Mutat Res 1996;362:237-48.
37. Asai T, Kambe F, Kikumori T, Seo H. Increase in Ref-1 mRNA and protein by thyrotropin in rat thyroid FRTL-5 cells. Biochem Biophys Res Commun 1997;236:71-4.
38. Suzuki S, Nagaya T, Suganuma N, Tomoda Y, Seo H. Inductions of immediate early genes (IEGS) and ref-1 by human chorionic gonadotropin in murine Leydig cell line (MA-10). Biochem Mol Biol Int 1998 Feb;44:217-24.
39. Flaherty DM, Monick MM, Carter AB, Peterson MW, Hunninghake GW. GM-CSF increases AP-1 DNA binding and Ref-1 amounts in human alveolar macrophages. Am J Respir Cell Mol Biol 2001;25:254-9.
40. Tanner B, Grimme S, Schiffer I, et al. Nuclear expression of apurinic/apyrimidinic endonuclease increases with progression of ovarian carcinomas. Gynecol Oncol 2004;92:568-77.
41. 6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 2005;11:2747-55.
42. Mendez F, Goldman JD, Bases RE. Abasic sites in DNA of HeLa cells induced by lucanthone. Cancer Invest 2002;20:983-91.
43. Luo M, Kelley MR. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res 2004;24:2127-34.
44. Del Rowe JD, Bello J, Mitnick R, et al. Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. Int J Radiat Oncol Biol Phys 1999;43:89-93.